Company
Synchron
We build implantable Brain-Computer Interfaces to protect what makes you human.
Also known as Synchron, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Synchron, Inc.
- synchron.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Synchron is pioneering interventional brain-computer interfaces, a category it created to scale neural interfaces to serve millions of people. Its first product, Stentrode™, is implanted via the jugular vein, and is currently being assessed in clinical trials to restore communication, independence and agency for people living with paralysis, in the USA, and Australia.
Funding snapshot
- Total raised
- $315MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $200M2025-11-06
Funding rounds
- Series D
- $200M2025-11-06, Company stated
- Series C
- $75M2022-12-13, Company stated
- Round, 2022
- $72.3M2022-11-07, SEC form D sold, 22 investors
- Round, 2021
- $32.6M2021-05-14, SEC form D sold, 14 investors
- Series B
- $40MCompany stated
Products
- Hardware
- Stentrode™
Loading relationship preview